Related Experiment Video
Updated: Jul 6, 2026
Magnetic Resonance Derived Myocardial Strain Assessment Using Feature Tracking
Published on: February 12, 2011
Precision phenomapping of pediatric dilated cardiomyopathy using clustering models based on electronic hospital
Xihang Fu1, Zubo Wu2, Jiawei Shi3
1Key Laboratory of Environment and Health, Ministry of Education & Ministry of Environmental Protection, Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No. 13, Hangkong Road, Wuhan, Hubei 430030, China.
Insights
This study identified two distinct subtypes of pediatric dilated cardiomyopathy (PDCM). One subtype presents with milder symptoms, while the other shows severe left ventricular dysfunction and a worse prognosis, guiding tailored treatment strategies.
Area of Science:
- Cardiology
- Pediatric Medicine
- Genetics
Background:
- Pediatric dilated cardiomyopathy (PDCM) is a complex and challenging disease to manage.
- Heterogeneity in PDCM necessitates the identification of distinct subtypes for improved clinical outcomes.
Purpose of the Study:
- To establish clinically relevant subtypes of PDCM.
- To evaluate the prognostic implications of identified PDCM subtypes.
- To guide personalized treatment strategies for PDCM.
Main Methods:
- Utilized a multicenter retrospective cohort of 279 idiopathic PDCM cases from electronic hospital records.
- Employed six clustering models for heterogeneous data to identify PDCM subtypes, with the Kamila model selected as optimal.
- Applied multivariable Cox models to assess the association between PDCM subtypes and adverse clinical events, and developed a clinical classifier.
Main Results:
- Identified two optimal PDCM phenotypes: Group I (infants/toddlers, larger dimensions, mild LV systolic dysfunction) and Group II (older children, severe LV systolic dysfunction, reduced LV wall thickness, higher prevalence of valvular regurgitation/arrhythmia).
- Group II exhibited significantly lower event-free survival compared to Group I (HR=8.096, P=0.002).
- A conditional interference tree model with five parameters accurately distinguished between the PDCM subtypes.
Conclusions:
- Distinct PDCM subtypes possess unique clinical profiles and varying risks of adverse prognosis.
- These identified subtypes likely respond differently to current therapies, paving the way for precision management.
- The findings offer novel directions for pathological studies and personalized treatment of PDCM.
Background:
Pediatric dilated cardiomyopathy (PDCM) is a heterogeneous disease, and its clinical management is still considered challenging. This study aimed to establish clinically relevant PDCM subtypes to evaluate prognosis and guide its treatments.
Methods:
Multidimensional data of study participants were derived from electronic hospital records based on a multicenter retrospective cohort in China. Six clustering models for heterogeneous data were adopted to identify PDCM subtypes, and multiple indices were used to select the best model. Multivariable Cox models were adopted to evaluate the association between PDCM subtypes and the risk of adverse clinical events. Finally, a clinical classifier was constructed for clinical application.
Results:
A total of 279 idiopathic PDCM cases were included in this study, and two phenotypes developed by the Kamila model were recognized as optimal. Group I was mainly infants and toddlers (median age: 6.32 months) with larger dimensions but mild systolic dysfunction of the left ventricle (LV) while group II was older children (median age: 111.77 months) with severe LV systolic dysfunction, reduced LV wall thickness, and higher prevalence of abnormal valvular regurgitation and arrhythmia. Moreover, group II had a significantly lower event-free survival probability than group I after adjusting for all covariates (HR = 8.096, P = 0.002). The conditional interference tree model with five parameters could accurately distinguish PDCM subtypes.
Conclusions:
PDCM subtypes in our study showed distinct clinical profiles and risks of worse prognosis, and probably have different responses to current standard therapies, which would provide novel directions for precision management and pathological studies of PDCM.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy